Arcutis Biotherapeutics, Inc. (ARQT) Dividend History

Company News

• Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

  Arcutis Biotherapeutics, a commercial-stage biopharmaceutical company, has granted 72,000 restricted stock units to nine newly hired employees as an inducement to join the company.

  GlobeNewswire Inc.
• Arcutis (ARQT) Stock Rises 31% in the Past Month: Here's Why - Zacks Investment Research

  Arcutis Biotherapeutics' Zoryve cream 0.15% has been approved by the FDA for the treatment of mild to moderate atopic dermatitis in adult and pediatric patients aged six years and older. The approval is based on positive data from two phase III studies, and the company plans to make the drug widely available by the end of July.

  Zacks Investment Research

  Featured Companies: ADPT ANIP RAPT
• Arcutis Biotherapeutics Stock Climbs After Blockbuster Q1 Results

  Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) reported its first-quarter financial results after the bell Tuesday. Here's a look at the highlights.  The Details: Arcutis Biotherapeutics reported quarterly earnings of 32 cents per share which beat the analyst consensus estimate of losses of 73 cents. Quarterly sales clocked in at $49.57 million, beating the analyst consensus estimate of $14.68 million by 237.66% and represented 1,680% increase over sales of $2.78 million from ...Full story available on Benzinga.com

  Benzinga